Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



The Effect of Darapladib Therapy for the Expression of Lp-PLA2 in Dyslipidemia and Type 2 Diabetes Mellitus Atherosclerosis Model

Titin Andri Wihastuti, Rosaria Dian Lestari, Teuku Heriansyah.




Abstract

Lipoprotein associated phospholipase A2 (Lp-PLA2) activity is suspected to contribute in atherosclerosis development. This study investigated the role of Lp-PLA2 and Lp-PLA2 selective inhibitor (darapladib) in atherogenesis. Conclucively, Darapladib significantly decreased Lp-PLA2 protein but was shown to increase the Lp-PLA2 mRNA levels in blood and aortic tissue in dyslipidemia and type 2 DM model.

Key words: darapladib, dyslipidemia, atherosclerosis, T2DM, Lp-PLA2, LP-PLA2 inhibitor






Full-text options


Share this Article


Online Article Submission
• ejmanager.com


ejPort - eJManager.com
Refer & Earn
JournalList
 About BiblioMed
License Information
Terms & Conditions
Privacy Policy
 Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.